GlassScriptPhysician profile
Khatereh A Assadi
NPI 1427327766
$1,034.60
in general payments reported to CMS, 2019-2025
14 companies · $493 in 2025
The $493 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.09 · 2021: $55.78 · 2023: $426 · 2024: $20.55 · 2025: $493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $940.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $939.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $282.66 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $160.82 | 2021-2024 | Arexvy, Shingrix |
| Lilly USA, LLC | $140.82 | 2019-2025 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $125.94 | 2023 | Breztri |
| Dexcom, INC. | $85.60 | 2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $37.92 | 2021-2023 | Gardasil 9, Pneumovax 23, Vaxneuvance |
| Viiv Healthcare Company | $32.16 | 2025 | Apretude |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.71 | 2023 | Stiolto Respimat, Spiriva Respimat, Jardiance |
| Abbvie INC. | $30.32 | 2023 | Qulipta |
| Alexion Pharmaceuticals, INC. | $25.70 | 2023 | Soliris |
| Exact Sciences Corporation | $24.98 | 2023 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $23.25 | 2019 | |
| Alkermes, INC. | $17.78 | 2023 | Aristada, Lybalvi |
| Cranial Technologies, INC | $15.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khatereh Assadi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.